Literature DB >> 1355403

Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.

W L McGuire1, A K Tandon, D C Allred, G C Chamness, P M Ravdin, G M Clark.   

Abstract

BACKGROUND: Every month, treatment decisions must be made for more than 6000 patients with breast cancer without axillary node involvement in the United States. Approximately 70% of these patients will survive more than 10 years after surgery and/or radiation treatment without additional systemic adjuvant therapy. If we had good methods to identify patients who are destined to have a recurrence of their disease, only those patients should receive adjuvant therapy.
METHODS: The authors reviewed the literature supporting the use of currently available prognostic factors for patients with node-negative breast cancer, and formulated a framework on which prognostic factor information can be based to help make these treatment decisions.
RESULTS: The steps involved in making treatment decisions are: use prognostic factors to determine the recurrence probability; calculate the expected treatment benefit; and weigh the expected benefits against the potential risks.
CONCLUSIONS: Prognostic factors can be used to help make treatment decisions for patients with breast cancer without axillary node involvement. However, the final treatment decision must take into account all aspects of the patient and her disease, and the physician must help the patient evaluate her prognostic factors, arrive at an understanding of her particular risk of recurrence, and weigh the potential benefits and risks of adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355403     DOI: 10.1002/1097-0142(19920915)70:4+<1775::aid-cncr2820701619>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Clinical and Histological Prognostic Factors in Axillary Node-Negative BreastCancer: Univariate and Multivariate Analysis with Relation to 5-Year Recurrence.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

2.  FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.

Authors:  W R Xing; K W Gilchrist; C P Harris; W Samson; L F Meisner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Modeling the effect of tumor size in early breast cancer.

Authors:  Claire Verschraegen; Vincent Vinh-Hung; Gábor Cserni; Richard Gordon; Melanie E Royce; Georges Vlastos; Patricia Tai; Guy Storme
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

4.  Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens.

Authors:  E E Lower; R S Franco; M A Miller; O J Martelo
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Predicting recurrence in axillary-node negative breast cancer patients.

Authors:  D Rosner; W W Lane
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Increased phosphotyrosine in breast cancer tissue is associated with a worse prognosis.

Authors:  E E Lower; M A Miller; L Williams; C Westermann; S Heffelfinger
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

7.  Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.

Authors:  S S Bacus; D Chin; Y Yarden; C R Zelnick; D F Stern
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

8.  Chemotherapy for advanced breast cancer: what influences oncologists' decision-making?

Authors:  E A Grunfeld; A J Ramirez; E J Maher; D Peach; T Young; I P Albery; M A Richards
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

9.  Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.

Authors:  M G Daidone; A Luisi; G Martelli; E Benini; S Veneroni; G Tomasic; G De Palo; R Silvestrini
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

10.  Prognostic significance of TP53 alterations in breast carcinoma.

Authors:  T I Andersen; R Holm; J M Nesland; K R Heimdal; L Ottestad; A L Børresen
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.